Advertisement

Topics

AbbVie Announces Depatuxizumab Mafodotin Fails to Demonstrate Survival Benefit in Phase 3 Glioblastoma Study

10:31 EDT 17 May 2019 | Speciality Pharma Journal

NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma (GBM), whose tumors have EGFR (epidermal growth factor receptor) amplification, demonstrated no survival benefit for patients receiving Depatux-M …

Original Article: AbbVie Announces Depatuxizumab Mafodotin Fails to Demonstrate Survival Benefit in Phase 3 Glioblastoma Study

NEXT ARTICLE

More From BioPortfolio on "AbbVie Announces Depatuxizumab Mafodotin Fails to Demonstrate Survival Benefit in Phase 3 Glioblastoma Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...